In 2001, the US Food and Drug Administration( FDA) approved Tracleer as the treatment for patients with PAH. Actelion develop the Tracleer and the sales of Tracleer grew rapidly due to a high patient switch over from off-label drugs to Tracleer. Tracleer, the major revenue generating drug of the PAH market is expected to go off patent by 2015.
Despite an increase in per-member-per-year spend from 2013 to 2014; trend for medications used to treat pulmonary hypertension is expected to be sluggish again in 2015, chiefly because of the market saturation of generic sildenafil. The global PAH market is expected to achieve highest sales till now in the year 2017 due to imminent release of the PAH drug called Uptravi( Selexipag) in 2016, which is anticipated to potentially drive the growth of the total market till 2019. Popularity of combinational therapies is also likely to drive the market in the aforementioned period.
Browse Complete Report @ http:// www. orbisresearch. com / reports / index / global-pulmonary-arterialhypertension-pah-market-trends-and-opportunities-2015-2019.
Some points from TOC: 1. Executive Summary
2. Pulmonary Arterial Hypertension( PAH): An Introduction 2.1 Definition of PAH 2.2 Classification of PAH 2.3 Causes of PAH 2.4 Who gets PAH? 2.5 How Serious is PAH? 2.6 Symptoms of PAH 2.7 Diagnosis of PAH 2.8 Treatment of PAH 2.8.1 Medications 2.8.2 Surgery 2.8.3 Lifestyle Changes 2.9 How does it affect?
For any enquires before buying, connect with us @ enquiry @ orbisresearch. com About Us:
Orbis Research( orbisresearch. com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information: www. orbisresearch. com; + 1( 214) 884-6817; + 9120-64101019